Onyx Pharmaceuticals (ONXX) +3.8% premarket as shares are upgraded to Outperform with a price...

|By:, SA News Editor

Onyx Pharmaceuticals (ONXX) +3.8% premarket as shares are upgraded to Outperform with a price target of $82 (from $65) at Leerink Swann. The firm says the failure of Bristol-Myers' (BMY -0.4%) brivanib to meet its primary survival objective is a "significant positive" for the long-term outlook for ONXX's Nexavar liver cancer treatment.